Home » Newsletters » BioWorld Science

BioWorld Science

May 3, 2018

View Archived Issues

Crysvita launched in U.S. for X-linked hypophosphatemia

SignalRx discovers selective BRD4-BD1 inhibitor

Merck KGaA and SFJ partner on abituzumab in metastatic colorectal cancer

Janssen to acquire Benevir Biopharm

YW-1128, a WNT pathway inhibitor, shows promising in vivo results for metabolic disorders

EMA approves Alpivab for the treatment of influenza

Enrollment ongoing in phase III trial of enfortumab vedotin for urothelial cancer

First-in-human study of hepatitis B DNA vaccine JNJ-64300535

Millennium Pharmaceuticals initiates first-in-human trial of TAK-164

FDA grants rare pediatric disease designation to CLR-131 for neuroblastoma

NeoImmuneTech enters clinical trial collaboration with Roche

MOR-106 moves into phase II development for atopic dermatitis with IGUANA trial

Patient enrollment ongoing in phase I study of CSJ-117 in atopic asthma

Lycera updates on ROR-gamma agonists LYC-54143 and LYC-55716

Hanmi opens first-in-human trial of HM-15211 in healthy obese subjects

FDA grants fast track designation to RGX-121 gene therapy

Arixa completes seed financing to advance oral avibactam prodrug ARX-1796

Microrod formulation of travoprost provides sustained release

FDA advisory committee votes on Achaogen's plazomicin for cUTI and bloodstream infections

Phase I data on CD34+ therapy presented for retinal degeneration

WHO grants INN seliforant to Sensorion's SENS-111

BIIB-092 shows safe pharmacodynamic activity in progressive supranuclear palsy trial

FDA issues complete response letter for Sandoz rituximab biosimilar

Araxes Pharma presents new mutant RAS inhibitors

Mission Therapeutics patents USP30 inhibitors

TES Pharma discovers ACMSD inhibitors

Novel mutant IDH inhibitors presented by Isocure Biosciences

Heptares Therapeutics divulges novel M1 and/or M4 receptor agonists

FDA advisory committee votes to recommend Siga's Tpoxx smallpox treatment

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
Anticancer drug exerts potent HIV antiviral effects
BioWorld Science
A new isoform of proliferating cell nuclear antigen (PCNA) – cancer-associated PCNA (caPCNA) – that is specifically expressed in cancer tissues has been reported....